Previous 10 | Next 10 |
Summary Shares of biotech concern Terns Pharmaceuticals are up some 150% after consummating a secondary offering at $2.42 a share, announced on August 12, 2022. Despite the bump, shares of Terns Pharmaceuticals are still down significantly from their IPO pricing back in January 20...
FOSTER CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, incl...
If there’s one thing that gets people going, it’s seeing what “big money” or “smart money” is doing. Quarterly and periodic filings from top Wall Street hedge funds tend to spark intrigue in certain companies. Meanwhile, “following the money&...
Gainers: Liberty TripAdvisor Holdings ( LTRPB ) +107% . Magic Empire Global Limited ( MEGL ) +94% . Viridian Therapeutics ( VRDN ) +54% . Qurate Retail ( QRTEB ) +43% . Intelligent Living Application Group ( ILAG ) +36% . MiN...
3 Things to Know About Buying Penny Stocks in August 2022 When it comes to buying penny stocks, there is a lot for traders to consider. Penny stocks for starters, are stocks that trade for less than $5 per share. While they can be a risky investment they also offer the potential for...
Terns Pharmaceuticals ( NASDAQ: TERN ) stock rose ~31% on Aug. 12 after it priced an offering to raise ~$65M in gross proceeds. The company is offering 12.25M common shares at $2.42 apiece and, to certain investors in lieu of common stock, pre-funded warrants to buy 14...
Gainers: Terns Pharmaceuticals ( TERN ) +36% . Rani Therapeutics ( RANI ) +25% . AirSculpt Technologies ( AIRS ) +21% . Larimar Therapeutics ( LRMR ) +21% . Neptune Wellness ( NEPT ) +18% . Losers: PLx Pharma ( PLXP ...
FOSTER CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, inclu...
Terns Pharmaceuticals press release ( NASDAQ: TERN ): Q2 GAAP EPS of -$0.55 beats by $0.08 . As of June 30, 2022, cash, cash equivalents and marketable securities were $139.8 million as compared with $166.0 million as of December 31, 2021. For further details see...
TERN-701 (allosteric BCR-ABL inhibitor) advances into Phase 1 trial for CML in China IND-enabling activities for TERN-601 (GLP-1R agonist) remain on track; Phase 1 obesity trial initiation expected in 2023 Initiated dosing of TERN-501 (THR-β agonist) Phase 2a ...
News, Short Squeeze, Breakout and More Instantly...
Terns Pharmaceuticals Inc. Company Name:
TERN Stock Symbol:
NASDAQ Market:
Terns Pharmaceuticals Inc. Website:
2024-07-20 09:30:00 ET Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the biggest contest of the moment will go to whoever can ramp up ...
2024-07-17 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
FOSTER CITY, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...